News
Sep 27, 2022
Arsenal Biosciences Announces Joint Discovery Collaboration with Genentech to Identify Features of Successful T-Cell Therapies for Oncology
Read MoreSep 6, 2022
Arsenal Biosciences Closes $220 Million Series B Financing to Advance Programmable Cell Therapy Programs into Clinical Development
Read MoreJan 10, 2022
ArsenalBio Announces Expansion of Collaboration with Bristol Myers Squibb to Advance T Cell Therapy in Solid Tumors
Read MoreNov 4, 2021
ArsenalBio Announces Participation in Upcoming Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
Read MoreOct 12, 2021